Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 17/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.69 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.69 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.69 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.69 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.69 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.69 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | STK16 | O75716 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.68 |
| ▸ | PRKCA | P17252 | 1/20 | 0.68 |
| ▸ | DCK | P27707 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613714 | 0.88 | MTOR (0.63) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL19299482 | 0.87 | MTOR (0.77) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL7903524 | 0.84 | MTOR (0.71) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16127231 | 0.83 | MTOR (0.75) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| Sapanisertib SCHEMBL7902875 | 0.82 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| Sapanisertib SCHEMBL29351459 | 0.82 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16117323 | 0.81 | BMPR1B (1.00) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL18613966 | 0.81 | RET (0.64) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL8012348 | 0.79 | SRC (0.56) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL27113591 | 0.79 | MTOR (0.73) | MTORPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683308-B2 | Rapamycin analogs and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683308-B2 | Rapamycin analogs and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190031683-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-20190031683-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| WO-2017044720-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031683-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | MTOR 2/4885PIK3CA 35/4885PIK3CD 123/4885 |
| US-10683308-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | MTOR 2/4885PIK3CA 35/4885PIK3CD 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.